Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor α inhibitor infliximab

Arthritis and Rheumatism

Volumn 54, Issue 12, 2006, Pages 3782-3789

  Bendtzen, Klaus ^a   Geborek, Pierre ^b   Svenson, Morten ^a   Larsson, Lotta ^b   Kapetanovic, Meliha C ^b   Saxne, Tore ^b  

^a Rigshospitalet   (Denmark)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; C REACTIVE PROTEIN; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; DRUG ANTIBODY; HYDROXYCHLOROQUINE; INFLIXIMAB; INFLIXIMAB ANTIBODY; METHOTREXATE; PREDNISOLONE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; AGED; ANAPHYLAXIS; ANTIBODY DETECTION; ARTHRALGIA; ARTICLE; BRONCHOSPASM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EARLY DIAGNOSIS; FATIGUE; FEMALE; HEADACHE; HUMAN; HYPOTENSION; IMMUNOGENICITY; INDIVIDUALIZATION; INFLAMMATORY DISEASE; INFLUENZA; MAJOR CLINICAL STUDY; MALE; MYALGIA; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RASH; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; TREATMENT FAILURE; URTICARIA; WHEEZING;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL AVAILABILITY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; DRUG TOLERANCE; FEMALE; HUMANS; IMMUNOGLOBULIN G; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; RADIOIMMUNOASSAY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33845660797     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.22214     Document Type: Article

References (26)

1. Maini R, St. Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al, for the ATTRACT Study Group. Infliximab (chimeric anti-tumor necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 1999;354:1932-9.
2. Lipsky PE, van der Heijde DM, St. Clair EW, Furst DE, Breedveld FC, Kalden JR, et al, for the Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000;343:1594-602.
3. Keating GM, Perry CM. Infliximab: an updated review of its use in Crohn's disease and rheumatoid arthritis. BioDrugs 2002;16:111-48.
4. Moreland LW. Drugs that block tumour necrosis factor: experience in patients with rheumatoid arthritis. Pharmacoeconomics 2004;22:39-53.
5. Baert F, Noman M, Vermeire S, van Assche G, D' Haens G, Carbonez A, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003;348: 601-8.
6. Wagner CL, Schantz A, Barnathan E. Olson A, Mascelli MA, Ford J, et al. Consequences of immunogenicity to the therapeutic monoclonal antibodies ReoPro and Remicade. Dev Biol (Basel) 2003;112:37-53.
7. Sandborn WJ. Optimizing anti-tumor necrosis factor strategies in inflammatory bowel disease. Curr Gastroenterol Rep 2003;5:501-5.
8. Gottlieb AB, Masud S, Ramamurthi R, Abdulghani A, Romano P, Chaudhari U, et al. Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-α monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris, J Am Acad Dermatol 2003;48:68-75.
9. Miele E, Markowitz JE, Mamula P, Baldassano RN. Human antichimeric antibody in children and young adults with inflammatory bowel disease receiving infliximab. J Pediatr Gastroenterol Nutr 2004;38:502-8.
10. Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004;350:876-85.
11. Feldmann M, Brennan FM, Foxwell BM, Taylor PC, Williams RO, Maini RN. Anti-TNF therapy: where have we got to in 2005? J Autoimmun 2005;25 Suppl:26-8.
12. Cheifetz A, Mayer L. Monoclonal antibodies, immunogenicity, and associated infusion reactions. Mt Sinai J Med 2005;72:250-6.
13. Anderson P, Louie J, Lau A, Broder M. Mechanisms of differential immunogenicity of tumor necrosis factor inhibitors. Curr Rheumatol Rep 2005;7:3-9.
14. Flendrie M, Creemers MC, Welsing PM, den Broeder AA, van Riel PL. Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis. Ann Rheum Dis 2003;62 Suppl 2:ii30-3.
15. Geborek P, Crnkic M, Petersson IF, Saxne T. Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden. Ann Rheum Dis 2002;61:793-8.
16. Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
17. Hennig C, Rink L, Fagin U, Jabs WJ, Kirchner H. The influence of naturally occurring heterophilic anti-immunoglobulin antibodies on direct measurement of serum proteins using sandwich ELISAs. J Immunol Methods 2000;235:71-80.
18. Bendtzen K. Anti-IFN BAb and NAb antibodies: a minireview. Neurology 2003;61 Suppl 5:S6-10.
19. St. Clair EW, Wagner CL, Fasanmade AA, Wang B, Schaible T, Kavanaugh A, et al. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46:1451-9.
20. Wolbink GJ, Voskuyl AE, Lems WF, de Groot E, Nurmohamed MT, Tak PP, et al. Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis 2005;64:704-7.
21. Wolbink GJ, Vis M, Lems W, Voskuyl AE, de Groot E, Nurmohamed MT, et al. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum 2006;54:711-5.
22. Haraoui B, Keystone EC, Thorne JC, Pope JE, Chen I, Asare CG, et al. Clinical outcomes of patients with rheumatoid arthritis after switching from infliximab to etanercept. J Rheumatol 2004;31:2356-9.
23. Solau-Gervais E, Laxenaire N, Cortet B, Dubucquoi S, Duquesnoy B, Flipo RM. Lack of efficacy of a third tumour necrosis factor α antagonist after failure of a soluble receptor and a monoclonal antibody. Rheumatology (Oxford) 2006;45:1121-4
24. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, et al. Therapeutic efficacy of multiple intravenous. infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552-63.
25. Gomez-Reino JJ, Carmona L. Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. Arthritis Res Ther 2006;8:R29.
26. Kapetanovic MC, Saxne T, Sjoholm A, Truedsson L, Jonsson G, Geborek P. Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. Rheumatology (Oxford) 2006;45:106-11.